Cyclotron Noordwest B.V. (Cyclotron Noordwest) and CircumSPECT Diagnostic and Services GmbH (CircumSPECT) are pleased to announce that as of March 21, 2025, they have signed an exclusive licensing agreement for the application of PET tracer [18F]-PSMA-JK-7 in the Netherlands.

This collaboration marks an important step towards making this PET tracer accessible to a broader group of prostate cancer patients. Parties will combine their expertise and resources to accelerate the registration and introduction of [18F]-PSMA-JK-7 in the Netherlands.

[18F]-PSMA-JK-7 has demonstrated its value in the Netherlands in recent years on a named patient basis for diagnosis of metastatic prostate cancer. Cyclotron Noordwest will file for the registration of [18F]-PSMA-JK-7 with authorities later in 2025. Registration is currently expected to be finalized in second half of 2026.

250324 Press Release Sublicense Agreement [18F] PSMA-JK-7